RAPT Therapeutics (NASDAQ:RAPT) Price Target Lowered to $1.00 at UBS Group

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) had its price objective lowered by stock analysts at UBS Group from $2.00 to $1.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a "neutral" rating on the stock. UBS Group's price objective indicates a potential upside of 4.71% from the stock's previous close.

Separately, HC Wainwright raised RAPT Therapeutics to a "strong-buy" rating and set a $6.00 target price on the stock in a report on Thursday, May 22nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, RAPT Therapeutics has an average rating of "Hold" and an average target price of $3.00.

RAPT Therapeutics Price Performance

Shares of NASDAQ:RAPT traded down $0.28 during midday trading on Thursday, reaching $0.96. The company had a trading volume of 1,896,345 shares, compared to its average volume of 1,280,006. The stock has a market capitalization of $126.34 million, a P/E ratio of -0.35 and a beta of -0.04. The stock's fifty day moving average price is $0.98 and its 200-day moving average price is $1.14. RAPT Therapeutics has a one year low of $0.71 and a one year high of $4.60.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.23. As a group, sell-side analysts forecast that RAPT Therapeutics will post -2.14 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in RAPT. Simplicity Wealth LLC bought a new stake in RAPT Therapeutics in the first quarter valued at $25,000. Picton Mahoney Asset Management lifted its position in RAPT Therapeutics by 994.4% in the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company's stock valued at $26,000 after purchasing an additional 14,697 shares during the last quarter. JPMorgan Chase & Co. lifted its position in RAPT Therapeutics by 298.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company's stock valued at $34,000 after purchasing an additional 25,130 shares during the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in RAPT Therapeutics during the 4th quarter valued at about $63,000. Finally, Sei Investments Co. bought a new position in RAPT Therapeutics in the 4th quarter worth about $64,000. 99.09% of the stock is currently owned by institutional investors.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.